Akero TherapeuticsAKRO
13F holders, Q4 2025 (December 31)2holders −263
0new positions
259sold out
$26.63avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Akero Therapeutics Inc. (AKRO) in their 13F filings, down 263 from Q3 2025. 0 opened new positions and 259 sold out. The largest holders were DekaBank Deutsche Girozentrale ($532K) and IFP Advisors, Inc ($984).
- Company
- Akero Therapeutics Inc.
- CUSIP
- 00973Y108
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 259 | $4.3B |
All 13F filers, Q3 2025 → Q4 2025: 9 shares bought and 91,348,172 shares sold, net −91,348,163 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 20,000 | $532K |
| IFP Advisors, Inc | 0.00% | Add +100.0% | 18 | $984 |
"% of holder's portfolio" is AKRO's weight in each manager's 13F, not the share of Akero Therapeutics Inc. the manager owns.